JZP 258

Drug Profile

JZP 258

Alternative Names: JZP-258; Oxybate mixed salt solution – Jazz Pharmaceuticals; Oxybate – Jazz Pharmaceuticals

Latest Information Update: 23 Mar 2017

Price : $50

At a glance

  • Originator Jazz Pharmaceuticals Inc
  • Class Hydroxybutyrates; Sleep disorder therapies; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cataplexy; Narcolepsy

Most Recent Events

  • 15 Mar 2017 Jazz Pharmaceuticals plans a phase III trial for Cataplexy and Narcolepsy in USA and EU
  • 15 Mar 2017 Jazz Pharmaceuticals completes a phase I trial in Cataplexy and Narcolepsy
  • 15 Mar 2017 Jazz Pharmaceuticals intends to submit NDA to the US FDA for Cataplexy and Narcolepsy in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top